Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx), an angiogenesis inhibitor, was the only drug approved for advanced patients until the 2017 / 2018 approvals of Stivarga (Bayer HealthCare), Opdivo and Yervoy (Bristol-Myers Squibb / Ono Pharmaceutical), Keytruda (Merck & Co.), Lenvima (Eisai / Merck & Co.), Cabometyx (Exelixis) and Cyramza (Eli Lilly). The late-phase development pipeline is predominantly focused on the advanced-stage HCC segment and encompasses a diverse range of mechanisms of action. The HCC market is majorly driven by approvals of premium-priced immune checkpoint inhibitors and expected uptake of combination regimens. Because the HCC market is largely untapped, the developer of an efficacious therapy could reap high commercial rewards.

Questions Answered

  • What is the current treatment landscape for HCC, and what clinical needs remain unfulfilled?
  • Which drug classes are in the late-phase development pipeline, and which agents are the most promising?
  • How is the drug-treatable HCC population defined, and how will drug-treatment rates change over time?
  • Which emerging therapies do we forecast to enter each of the HCC market segments?
  • What uptake and sales are these therapies anticipated to secure?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 20 country-specific interviews with thought leaders (medical oncologists and hepatologists).

Key companies: Bayer HealthCare / Amgen / Onyx , Bristol Myers Squibb / Ono Pharmaceutical, Merck & Co., Eisai, Exelixis / Ipsen, Eli Lilly.

Key drugs: Nexavar, Stivarga, Opdivo, Yervoy, Lenvima, Keytruda, Cabometyx, Cyramza.

Population segments in market forecast: Early-stage, first-line intermediate-stage, second-line intermediate-stage, first-line advanced-stage, and second-line advanced-stage hepatocellular carcinoma.

Emerging therapies: Phase III/PR: 5 drugs; Phase II: 18 drugs; coverage of select preclinical and Phase I products.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
    • Key Findings
    • Key Updates
      • May 2020
      • December 2019
      • July 2019
      • May 2019
      • December 2018
    • Market Outlook
      • Key Findings
      • COVID-19: Areas of Potential Forecast Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Hepatocellular Carcinoma?
        • What Factors Are Constraining the Market for Hepatocellular Carcinoma?
      • Segment-Specific Trends
        • Early-Stage Hepatocellular Carcinoma
        • Intermediate-Stage Hepatocellular Carcinoma
        • First-Line Advanced-Stage Hepatocellular Carcinoma
        • Second-Line Advanced-Stage Hepatocellular Carcinoma
    • Forecast
      • Market Forecast Downloads
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Disease Pathophysiology
      • Staging and Classification
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution of Hepatocellular Carcinoma
        • Recurrent Incident Cases of Hepatocellular Carcinoma
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Angiogenesis Inhibitors
        • Immune Checkpoint Inhibitors
      • Medical Practice
        • ​Early-Stage Hepatocellular Carcinoma
        • Intermediate-Stage Hepatocellular Carcinoma
        • Advanced-Stage Hepatocellular Carcinoma
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Hepatocellular Carcinoma
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Immune Checkpoint Inhibitors
        • Oncolytic Viral Therapies
        • Retinoid Nuclear Receptor Agonists
        • Cytotoxic Agents
      • Early-Phase Pipeline Analysis
      • Key Discontinuations and Failures in Hepatocellular Carcinoma
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Hepatocellular Carcinoma Bibliography

Author(s): Ananya Sadhu, Ph.D; Oliver Blandy

Ananya Sadhu, is an analyst with the oncology team at Decision Resources Group with expertise in multiple oncology indications including pancreatic cancer. Prior to joining Decision Resources Group, Dr. Ananya Sadhu was a postdoctoral fellow at National Centre of Biological Sciences, Bangalore, where she studied the role of chromatin architecture in regulating gene expression in breast cancer. Ananya holds a in Molecular Biology from National Institute of Immunology, New Delhi. She also worked as a Scientific Officer with Arvind Remedies Ltd., a pharmaceutical company, where she coordinated various stages of non-clinical / clinical research activities for drug development of a patented polyherbal formulation.

Oliver Blandy, BSc PGCE MSc, joined Decision Resources Group (DRG) as an Associate Epidemiologist in 2017. He focuses on the epidemiology of cancer. Oliver holds an MSc from the University of Bristol where he specialized in Nutrition, Physical Activity and Public Health. He also holds a BSc in Chemistry and has a Post Graduate Certificate in Education (PGCE), both from the University of Bristol and taught general science and Advanced Chemistry in high school for two years. Before joining the team at DRG, Oliver worked as a Research Assistant for Imperial College London where he was the lead for several studies within an NIRH funded research group that investigated healthcare associated infections and antimicrobial resistance.


Related Reports

Hepatocellular Carcinoma | Disease Landscape and Forecast | G7 | 2019

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx), an angiogenesis inhibitor, was t...

View Details

Hepatocellular Carcinoma | Geographic Focus: China | Hepatocellular Carcinoma | China In-Depth | China

MARKET OUTLOOK The hepatocellular carcinoma (HCC) market in China is poised to experience a sudden explosion in market growth. Availability of existing systemic agents...

View Details